Navigation Links
Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo

onders. Patients defined as responders by such criteria are in general able to function independently, having no or few deficits.

Improvement of clinical outcome was found with 47.4% of patients treated with 90 mcg/kg Desmoteplase and 36.4% of patients treated with 125 mcg/kg Desmoteplase, compared to 46.0% in the placebo group with neither dose of Desmoteplase statistically significantly different compared to placebo.

The rate of symptomatic intracranial bleeding within 72 hours after study drug administration was 0% in the placebo group, 3.5% in the 90 mcg/kg dose group and 4.5% in the 125 mcg/kg group. There were four patient deaths reported in the placebo group, three reported in the 90 mcg/kg dose group and 14 reported in the 125 mcg/kg dose group within the 90 day follow-up period. Ten of the 14 deaths in the 125 mcg/kg dose group were considered by the investigators as not related to the drug, 9 of which occurred 14 or more days after stroke and were from non-neurological causes.

These data are surprising and are not consistent with previously observed patterns in the DIAS/DEDAS trials and larger size, placebo-controlled acute stroke trials. The absence of consistency with previous findings is not easy to explain, but in-depth analyses are planned to better understand the data.

Forest will review the complete study database over the coming weeks to determine the appropriate next steps and its role regarding U.S. development of desmoteplase.

The headline results of the DIAS-2 study will be presented on 1 June 2007 at 10:45 a.m. BST within the "Large Clinical Trials II" session at the XVI European Stroke Conference in Glasgow, Scotland, U.K.

PAION will host a conference call on 1 June 2007 to discuss the DIAS-2 headline results starting at 1:00 p.m. BST (02:00 p.m. CEST, 08:00 a.m. EDT). To access the call please dial +44 20 7138 0819 UK, +49 69 9897 2634 Germany, +1 718 354 1361 USA. Title: "PAION DIAS-2 results"

<
'"/>




Page: 1 2 3 4

Related medicine technology :

1. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
2. CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone
3. CV Therapeutics Announces Topline MERLIN TIMI-36 Results
4. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
5. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/22/2008)...s from a multi-center 293-patient European, trial...hange Symbol: CYT, MONTREAL, July 22 /PRNewswire-...obal leader in cryotherapy products to treat cardi...ously presented from three,European study centers ...,were published earlier today in the Journal of th...
(Date:7/22/2008)...s Development Plan Completed Successfully, DUBLIN...n Corporation,plc (NASDAQ: AMRN ) today announced...he U.S. Food and Drug Administration (FDA) to disc...treatment of,hypertriglyceridemia. Following these... with AMR101 in hypertriglyceridemia., Dr. Declan...
(Date:7/22/2008)...ntus(R) and Apidra(R) Resulted in Significant, Red...hatever the Algorithm .../ -- Results from the "Adjust to,Target in Type 2 ...ohydrate,Counting for Adjustment of Mealtime Insul...n Diabetes Association,s (ADA) medical journal,Di...
(Date:7/22/2008)...h chemotherapy and pegylated enzyme produces si...rapy alone - - Pegylated enzyme w...irstCall/ -- Halozyme Therapeutics,Inc. (Nasdaq: ...d,commercializing products targeting the extracell...ositive pre-clinical animal efficacy data,for its ...
Breaking Medicine Technology:CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Whole Grains Do a Heart Good 4300 1Whole Grains Do a Heart Good 4300 2Whole Grains Do a Heart Good 4300 3Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 1Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 2Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 3Neptune Society Opens Tucson Arizona Office 4292 1Neptune Society Opens Tucson Arizona Office 4292 2Markel Expands Classes for Contagion Risk with OUTBREAK 28R 29 Extra Expense Coverage 4288 1Markel Expands Classes for Contagion Risk with OUTBREAK 28R 29 Extra Expense Coverage 4288 2
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... (SARS) epidemic in China has lessons to teach hos...ratory diseases// , according to new research appe... Diseases, currently available online. Hospitals ...n Guangzhou province and Hong Kong in 2003. In hos...
...fresh attack on genetically modified maize develop...ay that rats// fed on one version developed liver ...ad commissioned that was published in the journal ...n and Technology showed rats fed for 90 days on Mo...
...fying agent which could make vaccines for the H5N1...r to produce//. The development could help develo...ndemic struggling to access and afford the vaccine...ockpiled by developed countries. Researchers from...
... junk food in school canteens following a report b...DDRC in its report// has shown concern about the i...betes. A survey carried out by DDRC in 38 schools...n is clinically unhealthy or obese and junk food r...
Other Medicine News:Health News:Study Identifies Risk Factors for Spread of Respiratory Infections in Hospitals 2Health News:Brazilian Boost for Bird Flu Vaccines 2Health News:Brazilian Boost for Bird Flu Vaccines 3
Acetate Plate Sealers 100/Box
...croseal 'B' seals provide an adhesive-based sealin...tes. The aggressive adhesive layer ensures secure ...g, and tight sealing during thermal cycling when s...he perforated end-tabs can be removed when using t...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape.
Inquire
Medicine Products: